Editorial comments on: Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder, by E. Kaasinen et al. (in this issue).
a Department of Urology , National University of Singapore , Singapore.
Kesavan
K
Esuvaranathan
D000276:Adjuvants, Immunologic; D000283:Administration, Intravesical; D001500:BCG Vaccine; D002278:Carcinoma in Situ; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin; D009163:Mycobacterium bovis; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D001743:Urinary Bladder; D001749:Urinary Bladder Neoplasms
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D016685:Mitomycin